Publications — Radcliffe Department of Medicine

Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Novel Buffer Formulations for Improved Recombinant Lentiviral Vector Stability and In Vivo Delivery to the Murine Lungs

Miah KM. et al, (2023), MOLECULAR THERAPY, 31, 760 - 760

Type I interferon signaling deficiency results in dysregulated innate immune responses to SARS-CoV-2 in mice.

Ogger PP. et al, (2022), Eur J Immunol

Sendai F/HN pseudotyped lentiviral vector transduces human ciliated and non-ciliated airway cells using α 2,3 sialylated receptors

Munday RJ. et al, (2022), Molecular Therapy - Methods and Clinical Development, 26, 239 - 252

Progress in Respiratory Gene Therapy.

McLachlan G. et al, (2022), Hum Gene Ther, 33, 893 - 912

Correction of a chronic pulmonary disease through lentiviral vector-mediated protein expression

Lund-Palau H. et al, (2022), Molecular Therapy - Methods and Clinical Development, 25, 382 - 391

A High-Throughput Cell Culture Model of Idiopathic Pulmonary Fibrosis (IPF) for Gene Therapy Applications

Cerezuela MP. et al, (2022), MOLECULAR THERAPY, 30, 292 - 292

Development of Passive Immunoprophylaxis Against SARS-CoV-2 Using Elderly and Immunodeficient Mice Models

Du Y. et al, (2022), MOLECULAR THERAPY, 30, 11 - 12

F/HN Pseudotyped Lentiviral Vector Uses Alpha 2,3 Sialylated N-Acetyllactosamine to Efficiently Transduce Human Airway Cells

Munday RJ. et al, (2022), MOLECULAR THERAPY, 30, 12 - 12

SARS-CoV-2 Spike Protein-Pseudotyped Lentiviral Vectors (S-LV) for In Vitro and In Vivo Modelling of Emergent SARS-CoV-2 Variants

Miah KM. et al, (2022), MOLECULAR THERAPY, 30, 384 - 385

Lung directed antibody gene transfer confers protection against SARS-CoV-2 infection.

Du Y. et al, (2022), Thorax

Intranasal Lentiviral Vector-Mediated Antibody Delivery Confers Reduction of SARS-CoV-2 Infection in Elderly and Immunocompromised Mice.

Du Y. et al, (2022), Front Immunol, 13

Preclinical optimisation of lentiviral gene therapy delivery for surfactant deficiencies in piglets

McDougall C. et al, (2022), HUMAN GENE THERAPY, 33, A196 - A196

Aerosol-Mediated Non-Viral Lung Gene Therapy: The Potential of Aminoglycoside-Based Cationic Liposomes.

Le Gall T. et al, (2021), Pharmaceutics, 14

Genomic diversity of SARS-CoV-2 in Oxford during United Kingdom’s first national lockdown

Munis AM. et al, (2021), Scientific Reports, 11

Lentiviral and AAV-mediated expression of palivizumab offer protection against Respiratory Syncytial Virus infection

Antepowicz A. et al, (2021), Scientific Reports, 11

Identification of LZTFL1 as a candidate effector gene at a COVID-19 risk locus

DOWNES D. et al, (2021), Nature Genetics

Identification of LZTFL1 as a candidate effector gene at a COVID-19 risk locus.

Downes DJ. et al, (2021), Nat Genet, 53, 1606 - 1615

RNA-Seq Analysis of the Human Surfactant Air-Liquid Interface Culture Reveals Alveolar Type II Cell-like Transcriptome

Munis AM. et al, (2021), Molecular Therapy - Methods & Clinical Development

Functional characterisation of an engineered next generation lentivirus vector for the treatment of cystic fibrosis

Moiseenko A. et al, (2021), HUMAN GENE THERAPY, 32, A39 - A39

Lentiviral vector/GM-CSF Gene Therapy for Autoimmune Pulmonary Alveolar Proteinosis

Juarez-Molina CI. et al, (2021), HUMAN GENE THERAPY, 32, A38 - A38

Load More

1
2
3
4
5
6
7
...
»

Include forthcoming?